

## CURRICULUM VITAE

<b>Name:</b> Professor Philip M W Bath			
<b>Present appointment:</b>			
<ul style="list-style-type: none"> <li>• Chair and Head, Division of Stroke, University of Nottingham (1998-)</li> <li>• Stroke Association Professor of Stroke Medicine, University of Nottingham (1998-)</li> <li>• Acting Head, Division of Cardiovascular Medicine (2011-)</li> <li>• Honorary Consultant Physician, Nottingham University Hospitals NHS Trust (1998-)</li> <li>• Associate Director (Industry, Prevention), NIHR Stroke Research Network (2005-)</li> <li>• Member, Board of Directors, European Stroke Organisation (2007-)</li> <li>• NIHR Senior Investigator (2012-2015)</li> </ul>			
<b>Address:</b> Division of Stroke, University of Nottingham, Clinical Sciences Building, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham NG5 1PB			
<b>Telephone number:</b> +44 115 823 1765	<b>Email address:</b> philip.bath@nottingham.ac.uk		
<b>Qualifications:</b>			
B.Sc.	University of London	1979	Physiology
M.B., B.S.	University of London	1982	
M.R.C.P. (UK)	Royal College of Physicians	1986	
M.D.	University of London	1991	
G(I)M & CPT	RCP(L)	1993	
F.R.C.P.	Royal College of Physicians	1998	
Dip. Clin. Hypertension	European Society Hypertension	2002	
F.R.C.Path.	Royal College of Pathologists	2006	
<b>Professional registration:</b> General Medical Council; number: 2581530; full registration Aug 1983 onwards; <b>Insurance:</b> Medical Protection Society; number 134603			
<b>Previous and other appointments:</b>			
Wolfson Senior Lecturer in Stroke Medicine, King's College London, London (1993-8)			
<b>Research experience:</b>			
<ul style="list-style-type: none"> <li>• Head: Division of Stroke: funded by The Stroke Association, £0.7M over 5 years</li> <li>• Formerly Co-Director, Institute of Neuroscience, University of Nottingham (2008-9)</li> <li>• Research interests: Acute stroke treatment, recovery enhancement, dysphagia management; secondary prevention; antithrombotics; blood pressure lowering; lipid lowering; stem cells; trials</li> <li>• Chief Investigator/lead applicant: multicentre trials (MRC ENOS, £4.2M; Leo TAIST; TSA/AS PODCAST, £400K; BHF TARDIS, £310K; Phagenesis STEPS); single centre trials (GTN-1/2/3; UoN RIGHT; TSA STEMS-1; MRC STEMS-2; BHF TAST; Triple-1/2/3)</li> <li>• Co-applicant: MRC NeuroGrid, £2M; ESRC Stem Cells, £230K; DoH Stroke Research Network (Associate Director prevention/industry), £8M; DoH Trent Stroke Local Research Network £191K, UoN TICH, RfPB STEMS-3, EU FP7 EuroHYP (€10M)</li> <li>• Member, Trial Steering Committees: IMAGES, INTERACT, PRoFESS, SCAST, TESS-2</li> <li>• Data Monitoring Committees, Chair: AVERT, COOLIST, Euro-HYP, ME1-2, NXY-057 SA-NXY-0004, PISCES, Sipatrigine 137-104, TICH</li> <li>• Data Monitoring Committees, Member: CADISS, CHANT, IST-3, MCI-186-E04, SAINT-1/2</li> <li>• Local investigator: BRAVO, BW619C, CHARISMA, CLOTS-1/3, DNA lacunar, ESPRIT, FOOD, GV150526, IST, LubInt-13, MATCH, PERFORM, PROGRESS, ROCKET, SPARCL, SPORTIF-3, TRA-2P</li> </ul>			

### **PUBLICATIONS (Chief Investigator/Senior author, unless stated)**

1. Bath PMW. Alteplase not yet proven for acute ischaemic stroke. *Lancet* 1998;352:1238-9.
2. Bath PMW, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, Marttila R, Olsson J-E, O'Neill D, Ringelstein B, van der Sande J-J, Turpie AGG, for the TAIST Investigators. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. *Lancet* 2001;358:702-10.
3. Bath PMW, Pathansali R, Iddenden R, Bath FJ. The effect of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure and platelet function in acute stroke. *Cerebrovasc Dis* 2001; 11: 265-72.
4. The ENOS Trial Investigators. Glyceryl trinitrate versus control, and continuing versus stopping

- temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN 99414122). *Int J Stroke* 2006;1:245-9.
5. Sprigg N, Bath PMW, Zhao L, Willmot MR, Gray LJ, Walker MF, Dennis MS, Russell N. Granulocyte-colony stimulating factor mobilises bone marrow stem cells in patients with sub-acute ischaemic stroke: the 'Stem cell Trial of recovery EnhanceMent after Stroke' (STEMS) pilot randomised controlled trial (ISRCTN 16784092). *Stroke* 2006;37:2979-83.
  6. Willmot M, Ghadami A, Whysall B, Clarke W, Wardlaw J, Bath PM. Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. *Hypertension* 2006;47(6):1209-15.
  7. Sprigg N, Willmot MR, Gray LJ, Sunderland A, Pomeroy V, Walker M, Bath PM. Amphetamine increases blood pressure and heart rate but has no effect on motor recovery or cerebral haemodynamics in ischaemic stroke: a randomised controlled trial (ISRCTN 36285333). *J Hum Hypertens* 2007;19 April.
  8. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, et al; the PROFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent strokes. *New Engl J Med* 2008;359:1238-51. [Member, Trial Steering Committee; Co-chair, Substudies Committee; Member Publications Committee]
  9. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, et al; the PROFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. *New Engl J Med* 2008;359:1225-37. [Member, Trial Steering Committee; Co-chair, Substudies Committee; Member Publications Committee]
  10. Diener H-C, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Palesch Y, Martin RH, Bath P, et al, for the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) Study Group. Effects of aspirin plus extended-release dipyridamole and telmisartan on disability of recurrent stroke and cognitive function in patients with ischemic stroke: Results from the randomised Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) Trial. *Lancet Neurology* 2008;7:875-84. [Member, Trial Steering Committee; Co-chair, Substudies Committee; Member Publications Committee]
  11. Sprigg N, Gray LJ, England T, Willmot MR, Zhao L, Sare GM, Bath PM. A randomised controlled trial of triple antiplatelet therapy (Aspirin, Clopidogrel and Dipyridamole) in the secondary prevention of stroke: Safety, tolerability and feasibility (ISRCTN 83673558). *PLoS One*. 2008.
  12. Sare GM, Ali M, Shuaib A, Bath PMW, and for the VISTA Collaboration. Relationship between hyperacute blood pressure and outcome after ischemic stroke: data from the VISTA Collaboration. *Stroke* 2009; 40 (6): 2098-103. Epub 9 Apr 2009.
  13. Bath PMW, England TJ. Thigh-length compression stockings and DVT after stroke. *Lancet* 2009. Epub 27 May 2009. Editorial
  14. Geeganage C, Wilcox R, Bath PMW. Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis. *BMC Med* 2010; 8: 36.
  15. Geeganage C, Bath PMW. Vasoactive drugs for acute stroke. *Cochrane Database Syst Rev* 2010, 7, CD002839. Previously: 2000.
  16. Ankolekar S, Geeganage C, Anderton P, Hogg C, Bath PM. Clinical trials for preventing post stroke cognitive impairment. *J NeuroSci* 2010; 299:(1-2),168-74. Epub 20100919. Review [Senior Author]
  17. King A, Bath PM, Markus HA. Clopidogrel versus dipyridamole in addition to aspirin in reducing embolization detected with ambulatory transcranial doppler: a randomized trial. *Stroke* 2011;42:650-5. Epub 21 Jan 2011. [TSA grant co-applicant]
  18. Sandset EC, Bath PM, Boysen G, Jatuzis D, Körv J, Lüders S, Murray G, Richter PS, Roine RO, Terént A, Thijs V, Berge E; SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo controlled, double-blind trial. *Lancet* 2011;377:741-50. Epub 26 Feb 2011. [Member of Trial Steering Committee; advisor on analysis of primary outcome]
  19. England TJ, Auer DP, Abaei M, Love J, Russell N, Jones R, Sare G, Walker M, Bath PMW. Granulocyte-colony stimulating factor for mobilising bone marrow stem cells in sub-acute stroke: the Stem Cell Trial of Recovery EnhanceMent after Stroke-2 (STEMS-2) randomised controlled trial (ISRCTN 63336619). *Stroke* 2012;43:405-11 [MRC Lead grant applicant, Chief Investigator]

Philip Bath